X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Blockchain & supply chain resilience in the wake of Covid-19

Content Team by Content Team
27th April 2020
in News
Blockchain & supply chain resilience in the wake of Covid-19

The world is in the midst of the largest remote working experiment it has ever seen, reinforcing the value of reliable data. More than ever before, we need to know where our data comes from and whether or not it can be trusted. We are bombarded with information on a daily basis across the various different communication mediums we use in our professional and personal lives. This news is then passed onto each other sequentially, through emails, WhatsApp messages and other apps and social media platforms, and the velocity is only increasing, particularly in isolation.

Supply chains operate in the same way, linked sequentially in a chain that passes information from one user to the next. We rely on each constituent to do their part and pass on information quickly and accurately, but, like a Chinese whisper, the data is never the same at the end as it is at the beginning. However, what if we could guarantee that this information is accurate, immutable and derived from one of the most trusted sources of data capture? How could supply chains be transformed through the adoption of blockchain technology in times of crisis and in times of normality?

Most organisations are active in two supply chains, one physical and one financial. The financial one has the distinct advantage of being born digital while the physical one remains analogue and therefore significantly slower. Both need to be measured, monitored and tracked, so that the data extracted can be analysed and used to drive the next level of industrial automation, Industry 4.0.

However, what if one link is out of action being furloughed or unwell? How can the adjacent links maintain the bridge and keep the information and the supply chain moving?

COVID-19 risks to each link/person in the supply chain, much like a row of dominoes toppling until one link is missing. According to McKinsey, some 38% of supply chains are digitised and very few are using blockchain technology – the key to unlocking the connectivity.

Today’s supply chains are global, connected and generally efficient. Still, Covid-19 has placed a spotlight on our weaknesses. The focus on cost efficiency throughout supply chains demands evidence-based delivery: every component and process needs to be tracked to ensure that the final product can be verified and tracked back to its component parts, identifying where cost savings can be made and whether organisations are operating in the most efficient way possible.

Blockchain is the technology behind a distributed network of computers that can be used to store data securely but which, uniquely, has a single memory. That means data cannot be freely copied and edited to create an alternative version of the truth, which is why blockchain technologists refer to it as the “trust platform”. In the enterprise context, the blockchain would be used as a private permissioned framework for a group of stakeholders, such as suppliers, customers and regulators.

A recent survey by HFS Research and Wipro found that of 318 senior executives polled, 75 percent consider blockchain to be a strategic priority. This will only continue to grow as accountability, auditability and cost efficiencies within supply chains are increasingly prioritised. After all, duplication, checking and re-checking data and its sources costs time and money, slowing down supply chain processes. Furthermore, nearly 60% of these C-level executives anticipate that consensus-driven trust allows them to plan entirely new business models that were not possible before blockchain.

The global impact of COVID-19 will force us to reconsider what we want from our supply chains, whether this be costs efficiencies, or increased speed and agility. Unlike a row of dominoes, we also need supply chains that can withstand the next pandemic by creating a circle of trust, and not a sequential line with points that can fail.

Previous Post

Cytovance and Akshaya Bio Announce Collaboration Agreement of Therapeutics for Treatment of Coronavirus and Hepatitis B Virus Infections

Next Post

CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19

Related Posts

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
America Facing Heart Health Issues Since The Pandemic Began
News

America Facing Heart Health Issues Since The Pandemic Began

8th February 2022
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants
News

T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

7th February 2022
OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis
Manufacturing

Lilly announces $1 billion investment in new manufacturing facility in North Carolina

7th February 2022
Recipharm supports FDA approval of Perrigos AB-rated generic product
News

Recipharm acquires GenIbet to bolster Biologics offering

7th February 2022
Next Post
CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19

CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In